WO2005028458A1 - Preparation of quetiapine - Google Patents

Preparation of quetiapine Download PDF

Info

Publication number
WO2005028458A1
WO2005028458A1 PCT/FI2004/000560 FI2004000560W WO2005028458A1 WO 2005028458 A1 WO2005028458 A1 WO 2005028458A1 FI 2004000560 W FI2004000560 W FI 2004000560W WO 2005028458 A1 WO2005028458 A1 WO 2005028458A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
salt
formula
ethyl
acetyl
Prior art date
Application number
PCT/FI2004/000560
Other languages
French (fr)
Inventor
Petteri Rummakko
Soini Huhta
Arne Grumann
Original Assignee
Fermion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US50498103P priority Critical
Priority to US60/504,981 priority
Application filed by Fermion Oy filed Critical Fermion Oy
Publication of WO2005028458A1 publication Critical patent/WO2005028458A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16[b, f]-condensed

Abstract

The present invention discloses a process for the preparation of quetiapine, which comprises the ring closure of a compound of the formula shown below, as well as novel intermediates in the process.

Description

PREPARATION OF QUETIAPINE
The present invention is directed to a new method for the preparation of quetiapine. Further objects of the invention are novel intermediates useful in the process according to the invention.
BACKGROUND OF THE INVENTION
l l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,f]-l,4-thiazepme (I) is a well established drag substance known under the INN name quetiapine.
Figure imgf000002_0001
I
It is used as hemifumarate salt as an antipsychotic or neuroleptic.
Several methods for the preparation of quetiapine are known, as disclosed in e.g. GB 8607684, GB 8705574, and WO 01/55125. The known methods include reacting a halo derivative (e.g. iminochloride) of dibenzo[b,f][l,4]-thiazepin-l l(10- H)-one with l-(hydroxyethoxyethyl)piperazine; reacting the aforementioned halo derivative with piperazine and reacting the resulting intermediate with a haloethoxyethanol; and reacting a haloethylpiperazinylthiazepine derivative with ethylene glycol.
SUMMARY OF THE INVENTION
The present invention is directed to a method for the preparation of the compound of formula I or a salt thereof
Figure imgf000003_0001
by cyclization of a compound of formula II or a salt thereof
Figure imgf000003_0002
II
wherein RΪ is a hydroxyl protecting group selected from the group consisting of acetyl, benzoyl, pivaloyl, benzyl, 4-methoxybenzyl, allyl, tetrahydropyranyl, silyl, alkyl carbonate, aryl carbonate, aralkyl carbonate, benzyl carbonate, allylsulfonyl, benzylsulfonyl, toluenesulfonyl and R2 is H or a suitable amino protecting group , e.g. acetyl, pivaloyl or benzyl to produce a compound of formula III or a salt thereof
Figure imgf000003_0003
in which R\ is defined as above, which on removal of R\ yields compound I or a salt thereof.
The compound of formula I or a salt thereof can be further reacted to a pharmaceutically acceptable salt thereof, e.g. hemifumarate. The inventors have surprisingly noticed that the thiazepine ring closure takes place in Nilsmeier reaction conditions even though both hydroxyl and aniline moiety are acetate protected. To the knowledge of the inventors this kind of reaction is previously unknown and offers a novel method for the preparation of quetiapine and other thiazepines.
Selective hydroxyl group protection of intermediate V is difficult to perform. For example, if acetylation is used, a mixture of mono O-acetate and diacetylated compounds is frequently obtained. The possibility of using the diacetylated compound in ring closure reaction step makes the whole process more easy to work. It is also possible to use mixtures of mono O-acetate and diacetate in the ring closure step.
The invention also includes the novel intermediate compounds II defined above and salts thereof, and further compounds of formula IV and salts thereof
Figure imgf000004_0001
rv wherein LG is a leaving group, e.g. halogen, diazonium, trifluoromethyl, O- trifiuoromethane-sulfonyl, O-p-toluenesulfonyl or O-methanesulfonyl, preferably halogen or diazonium.
Compounds I to VII can also be used and prepared as suitable salts thereof, e.g as acetates or hydrochlorides.
DISCLOSURE OF THE INVENTION
According to the present invention, cyclization of compound II yields compound ILT, which on hydroxyl deprotection yields the target compound, quetiapine, which can be further reacted to a pharmaceutically acceptable salt, e.g. hemifumarate. Preferably, the ring closure takes place under Vilsmeier conditions in the presence of a chlorinating agent and optionally in the presence of a strong tertiary amine base. Possible chlorinating agents include but are not limited to POCl3, SOCl2, PC13, PCI5, COCl2, and (COOCl)2; preferably, the reagent is POCl3. The chlorinating agent may be used in large excess but preferably 4 to 5 molar equivalent is used. Possible bases include triethylamine, di-isopropylethylamine, DABCO, N,N- dimethylamine and triethylenediamine. The reagent can act as a solvent, but also a co-solvent selected e.g. from toluene, xylene, acetonitrile and chlorinated hydrocarbons can be used. Preferred co-solvents, if used, are toluene, acetonitrile and mixtures of these. Carboxylic acids, e.g. acetic acid, water, inorganic acids and alcohols can be used as beneficial additives in this reaction. The reaction temperature and the duration are dependent on the solvent used; advantageously reflux temperature or a temperature close thereto is used. For example, the temperature may be in the range 50 - 120 °C and the reaction time in the range of 0,5 to 6 h.
Compound LU may be deprotected by saponification using a suitable base in an alcohol to give quetiapine. Preferably, the reaction takes place with aqueous alkali metal hydroxide in methanol, ethanol or 2-propanol. Quetiapine base can be converted to a pharmaceutically acceptable salt, e.g. hemifumarate by methods known in the art and purified further e.g. by crystallization from a suitable solvent.
Rt and R may be introduced individually or in one step by reaction of intermediate V or a salt thereof with one or more reagents reactive towards amino and/or hydroxyl groups.
Figure imgf000005_0001
According to a preferable embodiment of the present invention, compound π or a salt thereof is represented by the diacetyl compound VI or a salt thereof, which is obtained by acetylation of intermediate V or a salt thereof.
Figure imgf000006_0001
VI
According to another embodiment of the present invention, compound II or a salt thereof is represented by the mono-, i.e. O-acetylated compound VII or a salt thereof,
Figure imgf000006_0002
VII obtainable under non-exhaustive acetylation conditions. Acetylation may also result in a mixture of mono- and diacetylated product, which may be used in place of the pure intermediates.
Acetylation may be carried out in a mixture of acetic acid and acetic anhydride or acetyl chloride with or without cosolvent. Possible cosolvents include ethers, esters, aromatic hydrocarbons, chlorinated hydrocarbons, ketones and acetonitrile. The temperature maybe in the range of 0-120 °C, and the reaction time 1-20 h. If the diacetylated compound is prepared, acetylation reagent is used with 1 to 3 fold excess.
Intermediate V or a salt thereof may be obtained by coupling of 2-aminothiophenol with intermediate IV or a salt thereof, which can be used either isolated or a crude product from the reaction between compound of formula VIII or a salt thereof and l-[2-(hydroxyethoxy)-ethyl]-piperazine.
Figure imgf000007_0001
TV
LG represents a leaving group, e.g. halogen, diazonium, trifluoromethyl, O-p- toluenesulfonyl or O-methanesulfonyl. The reaction is carried out optionally in the presence of a metal catalyst, a base and a ligand compound in a solvent.
Useful metal catalysts include palladium, nickel and copper compounds. Preferable catalysts are copper iodide and copper bromide. Useful solvents include water, ionic liquids, alcohols, polyethylene glycol, N,N-dimethylformamide, toluene, acetonitrile and mixtures thereof. Preferably, the solvent is water or an alcohol or the mixture of these. The base present may be organic or inorganic; preferably, the base is potassium carbonate. The ligand compound may be a diol, a diamine, an aminoalcohol or EDTA. Preferably, if the ligand compound is used, it is ethylene glycol.
The reaction temperature and duration are dependent on the solvent used. For example, the temperature range may be 50 -120 °C and the reaction time 1 - 20 h.
Intermediate TV may be prepared by reaction of l-[2-(hydroxyethoxy)-ethyl]- piperazine with a compound of formula VIII
CO" VIII wherein LG is defined as above and AG is a typical carboxylic acid activating group, e.g. halogen, alkyloxy, aryloxy, mixed aliphatic or aromatic anhydride, azide or carbodiimide.
The reaction may be carried out in the presence of a base. Possible solvents include water, aromatic hydrocarbons, chlorinated hydrocarbons, esters and ethers or their mixtures with water. Triethylamine, other tertiary amines or inorganic bases may be used. Preferably the reaction is carried out in water without a base. The reaction takes place in ambient temperature, but any temperature between 0- 100 °C maybe used.
The following examples merely illustrate the invention and they are not to be construed as limiting.
EXAMPLES
Example 1. a. {4-[2-(2-hydroxy-ethoxy)ethyl- piperazin-l-yI}-(2-iodophenyl)- methanone
2-iodobenzoic acid (20 g, 0,081 mol), toluene (20 ml) and thionyl chloride (30 ml, 0,41 mol) were charged into a reaction flask. The mixture was stirred and refluxed for 11 h. Toluene (40 ml) was added and the solvent and excess of thionylchloride were distilled off under reduced pressure. The process was repeated with 20 ml of toluene. The residue of 2-iodobenzoyl chloride was dissolved into THF (20 ml). l-[2-(hydroxyethoxy)-ethyl]-piperazine (14,1 g, 0,081 mol), THF (100 ml), water (50 ml) and triethylamine (12,3ml) were added into a reaction flask and stirred at icewater bath temperature. The previously prepared 2-iodobenzoyl chloride THF solution was slowly added to the reaction mixture. The temperature was kept below 20 °C during the addition. The reaction mixture was allowed to warm to room temperature and stirred 2 h at ambient temperature. 50 ml of water was added and THF was removed by distillation. The pH of the solution was checked and adjusted to 9-10. The water was extracted three times with dichloromethane (50 ml). The combined organic phase was evaporated yielding {4-[2-(2-hydroxy-ethoxy)ethyl- piperazin-1-yl} -(2-iodophenyl)- methanone as a yellowish oil, which was used without further purification. Yield 31 g.
1H NMR (CDC13): 2.42 (1H, m), 2.63 (5H, m), 3.25 (2H,m), 3.59 (2H,m), 3.68 (4H, m), 3.90 (3H, m), 7.06 (1H, t), 7.18 (1H, d), 7.40 (1H, t), 7.83 (1H, d). 13C NMR (CDC13): 41.3, 45.9, 46.6, 52.7, 53.4, 57.7, 61.9, 67.8, 72.4, 92.5, 127.0, 128.4, 130.2, 139.2, 142.1, 169.1.
b. 2-(2-amino-phenylsulfanyl)-phenyl-{4(2-(2-hydroxyethoxy)ethyIpiperazin- l-yl} methanone {4-[2-(2-hydroxy-ethoxy)ethyl- piperazin- 1 -yl} -(2-iodophenyl)- methanone (10 g, 0,025 mol) was dissolved in isopropanol (50 ml) and ethylene glycol (2,5 ml). Cul (0,24 g , 5 mol %) and K2CO3 (6,9 g) were added to the reaction mixture. The reaction vessel was flushed with nitrogen, and 2-aminothiophenol (3,4 g, 0,028 mol) was added under a nitrogen atmosphere. The reaction mixture was refluxed overnight (12-18 h). Solid material was filtered off and the solvent was evaporated. The residue was dissolved in ethyl acetate (100 ml) and washed once with 1 M NaOH (25 ml). Water (100 ml) was added and the pH was adjusted to 5 with dilute acetic acid. The organic layer was washed once with water (50 ml) and the water phases were combined. The pH of the water was adjusted to 10-11 with 1 M NaOH and the basic water phase was extracted twice with ethyl acetate (100 ml). The combined organic phases were evaporated to afford [2-(2-amino-phenylsulfanyl)- phenyl-{4(2-(2-hydroxyethoxy)ethyl]piperazin-l-yl} methanone as a dark red oil, yield 8,8 g. 1H NMR (CDC13): 2.51 (2H, s), 2.64 (4H, m), 3.36 (2H, m), 3.60-3.71 (6H, m), 3.90 (2H, s, broad), 4.46 (2H, s), 6.73 (2H, m), 6.94 (1H, m), 7.15-7.29 (4H, m), 7.45 (1H, d).
13C NMR (CDC13): 41.4, 46.8, 52.9, 53.7, 57.8, 61.9, 67.8, 72.4, 113.8, 115.4, 118.2, 126.1, 126.4, 128.4, 129.5, 131.3, 133.9, 135.7, 137.4, 149.3, 168.5.
Steps a and b can also be performed in one pot without isolation of the intermediate made in step a. c. [2-(2-acetamino-phenylsulfanyI)-phenyl]-{4(2-(2-acetoxyethoxy)ethyl]- piperazin-1-yl} methanone
[2-(2-amino-phenylsulfanyl)-phenyl]- {4(2-(2-hydroxyethoxy)ethyl]piperazin- 1 -yl} methanone (10,7 g, 0,027 mol) was dissoved in ethyl acetate (50 ml) and triethylamine (7,4 ml) was added into reaction mixture. Acetic anhydride (7,6 ml, 0,08 lmol) was slowly added to the reaction mixture at room temperature. After 4 h, the reaction mixture was evaporated to give a dark blue oil which was dissolved in ethyl acetate (50 ml) and washed with 2x25 ml saturated NaHCO3 solution and once with brine. The organic phase was evaporated to give a brown oil (10,9 g). The residue of [2-(2-acetamino-phenylsulfanyl)-phenyl- {4(2-(2-acetoxyethoxy)ethyl]- piperazin-1-yl} methanone was used further without purification. 1H NMR (CDC13): 2.04 (3H, s), 2.08 (3H, s), 2,49 (2H,m), 2.66 (4H,m), 3.29 (2H, s,broad), 3.66 (3H, m), 3,90 (IH, m), 4.21 (2h, d), 7,07 (IH, t),7,08-7,39 (3h,m), 7,61 (IH, t), 7,63 (IH, d), 8,34 (IH, d), 8,80 (IH, s). 13C NMR (CDC13): 21.0, 24.3, 41.7, 47.0, 53.1, 53.8, 63.4, 68.8, 69.0, 121.3, 122.2, 123.8, 126.1, 127.5, 130.0, 130.6, 131.5, 132.8, 136.3, 137.0,140.2, 168.7, 169.6, 170.9.
d. ll-(4-[2-(2-acetyloxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,fJ-l,4-thiazepine [2-(2-acetamino-phenylsulfanyl)-phenyl- {4(2-(2-acetoxyethoxy)ethyl]piperazin- 1 - yl} methanone (2 g, 0,0041 mol) was dissolved in POCl3 (5 ml) and stirred at room temperature for 30 min. The mixture was slowly heated to reflux and refluxed for 3 h. Excess of POCl3 was evaporated and water 50 ml and methanol (5 ml) were carefully added to the residue. The mixture was stirred at room temperature until all material was dissolved. The pH of the water was adjusted to 10-11 by addition of NaOH followed by extraction with toluene 2x50 ml. The organic layer was separated and evaporated to give a dark residue of 1 l-(4-[2-(2-acetyloxy- ethoxy)ethyl]- l-piperazinyl]dibenzo[b,fJ-l,4-thiazepine (1,53 g). 1H NMR (CDC13): 2.06 (3H, s), 2.52-2.67 (6H, m), 3.46-3.68 (8H, m), 4.21 (2H, m), 6.68 (IH, t), 7.06 (IH, d), 7.16 (IH, t), 7.31 (3H, m), 7.38 (2H, d), 7.50 (IH, d). 13C NMR (CDC13): 20.9, 46.7, 47.6, 53.4, 57.8, 63.4, 68.9, 70.0,122.8, 125.3, 128.0, 128.2, 129.0, 129.1, 130.7, 132.1, 132.2, 134.2, 140.0, 148.9, 160.7, 171.0. e. Quetiapine base
The residue of ll-(4-[2-(2-acetyloxyethoxy)ethyl]- l-piperazmyl]dibenzo[b,f]-l,4- thiazepine (7,8 g) was dissoved in ethanol (50 ml) and 1M NaOH solution (55 ml) was added. The mixture was stirred at room temperature for 30 min. The product was extracted into toluene (2 x 100 ml). Evaporation of the toluene phase gave quetiapine base (6,9 g).
Example 2
Steps a and b as in example 1. c. Dihydrobromide salt of [2-(2~amino-phenyIsulfanyI)-phenyl-{4(2-(2- hydroxyethoxy)ethyl]piperazin-l-yl} methanone
The evaporation residue of [2-(2-amino-phenylsulfanyl)-phenyl-{4(2-(2- hydroxyethoxy)ethyl]piperazin-l-yl} methanone (example 2) (7,5 g , 0,019 mol) was dissolved in 2-propanol (40 ml). The mixture was heated to 80 °C, and a 34% solution of HBr in AcOH (9,3 g , 2,1 mol) was slowly added to the almost refluxing mixture. The solution was slowly allowed to reach room temperature and finally kept 30 min in an ice water bath. The precipitated product was filtered and washed with cold 2-propanol to afford the dihydrobromide as a pale grey powder (7.4 g).
d. [2-(2-amino-phenylsulfanyl)-phenyl-{4(2-(2-acetoethoxy)ethyl]piperazin-l- yl} methanone x 2 HBr
Compound [2-(2-amino-phenylsulfanyl)-phenyl- {4(2-(2- hydroxyethoxy)ethyl]piperazin-l-yl} methanone x 2 HBr (5 g, 0,009 mol) was dissoved in acetic acid and heated until all solid material was dissolved. Acetic anhydride (0,96 ml, 0,010mol) was slowly added to the warm reaction mixture at ca. 50 °C. The reaction was continued for 2 h at constant temperature. After 2 h the reaction mixture was evaporated to give a dark blue oil (7.3 g) which still contained some acetic acid. HPLC from the residue showed 95 % pure [2-(2-amino- phenylsulfanyl)-phenyl-{4(2-(2-acetoxyethoxy)ethyl]piperazin-l-yl} methanone x 2 HBr, and it was used without further purification.
Ring closure and deprotection may be carried out in accordance with steps d and e of example 1.

Claims

1. A method for the preparation of the compound of formula I or a salt thereof
Figure imgf000012_0001
I by cyclization of a compound of formula II or a salt thereof
Figure imgf000012_0002
II wherein Rι is a hydroxyl protecting group selected from the group consisting of acetyl, benzoyl, pivaloyl, benzyl, 4-methoxybenzyl, allyl, tetrahydropyranyl, silyl, alkyl carbonate, aryl carbonate, aralkyl carbonate, benzyl carbonate, allylsulfonyl, benzylsulfonyl, toluenesulfonyl and R2 is H or a suitable amino protecting group , e.g. acetyl, pivaloyl or benzyl to produce a compound of formula III or a salt thereof
Figure imgf000012_0003
III
in which R\ is defined as above, which on removal of Ri yields compound I or a salt thereof.
2. A process according to claim 1 where compound of formula I is further reacted to a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the cyclization is carried out using phosphorus oxychloride.
4. The method of claim 1 , wherein the compound of formula II or a salt thereof is obtained by coupling of 2-aminothiophenol with a compound of formula IV or a salt thereof,
Figure imgf000013_0001
TV wherein LG represents halogen, diazonium, trifluoromethyl, O-p-toluenesulfonyl, O-trifluoromethanesulfonyl or O-methanesulfonyl and reacting the resulting intermediate with at least one reagent providing at least the protective group R1; and optionally R2.
5. The compound of formula TV, wherein LG is I or Br.
6. [2-(2-amino-phenylsulfanyl)-phenyl-{4(2-(2-hydroxyethoxy)ethyl]piperazin-l- yl} methanone.
7. The compound of formula
Figure imgf000013_0002
wherein Ri and R2 are defined as in claim 1.
8. The compound of claim 7, wherein R\ and R2 are both acetyl.
9. The compound of claim 7, wherein R is acetyl and R2 is H.
0. (4-[2-(2-acetyloxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,fj-l,4-thiazepine.
PCT/FI2004/000560 2003-09-23 2004-09-23 Preparation of quetiapine WO2005028458A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US50498103P true 2003-09-23 2003-09-23
US60/504,981 2003-09-23

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE602004024798T DE602004024798D1 (en) 2003-09-23 2004-09-23 PREPARATION OF QUETIAPINE
EP04767074A EP1664007B1 (en) 2003-09-23 2004-09-23 Preparation of quetiapine
AT04767074T AT452882T (en) 2003-09-23 2004-09-23 PREPARATION OF QUETIAPINE
JP2006526653A JP2007505864A (en) 2003-09-23 2004-09-23 Manufacture of quetiapine
US10/572,409 US7863441B2 (en) 2003-09-23 2004-09-23 Preparation of quetiapine
CA002538745A CA2538745A1 (en) 2003-09-23 2004-09-23 Preparation of quetiapine

Publications (1)

Publication Number Publication Date
WO2005028458A1 true WO2005028458A1 (en) 2005-03-31

Family

ID=34375548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2004/000560 WO2005028458A1 (en) 2003-09-23 2004-09-23 Preparation of quetiapine

Country Status (9)

Country Link
US (1) US7863441B2 (en)
EP (1) EP1664007B1 (en)
JP (1) JP2007505864A (en)
AT (1) AT452882T (en)
CA (1) CA2538745A1 (en)
DE (1) DE602004024798D1 (en)
ES (1) ES2335589T3 (en)
PT (1) PT1664007E (en)
WO (1) WO2005028458A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2010100623A1 (en) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
CN101891707A (en) * 2010-07-29 2010-11-24 浙江海正药业股份有限公司 Method for preparing Quetiapine or pharmaceutically acceptable fumarate thereof
US8101597B2 (en) 2007-05-07 2012-01-24 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
US8420807B2 (en) 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine
CN103396382A (en) * 2013-07-29 2013-11-20 太仓市茜泾化工有限公司 Preparation method of quetiapine intermediate
WO2014031600A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of quetiapine for use in immunoassays
US9012648B2 (en) 2012-08-21 2015-04-21 Janssen Pharmaceutica Nv Haptens of risperidone and paliperidone
CN104854110A (en) * 2012-08-21 2015-08-19 詹森药业有限公司 Haptens of olanzipine
US9394354B2 (en) 2012-08-21 2016-07-19 Janssen Pharmaceutica Nv Haptens of paliperidone
US9410972B2 (en) 2012-08-21 2016-08-09 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US9465041B2 (en) 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
US9494607B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
US9504682B2 (en) 2012-08-21 2016-11-29 Janssen Pharmaceutica Nv Haptens of aripiprazole
US9611332B2 (en) 2012-08-21 2017-04-04 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
US9664700B2 (en) 2012-08-21 2017-05-30 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US9751953B2 (en) 2012-08-21 2017-09-05 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
US9850318B2 (en) 2012-08-21 2017-12-26 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
US10370457B2 (en) 2012-08-21 2019-08-06 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10712353B2 (en) 2012-08-21 2020-07-14 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664009B1 (en) * 2003-09-23 2011-01-19 Fermion Oy Preparation method for quetiapine
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
CN104803947A (en) * 2015-03-12 2015-07-29 常州康丽制药有限公司 Preparation method of 11-(1-piperazinyl) dibenzo[b, f][1,4] thiazepine fumarate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
WO2001055125A1 (en) * 2000-01-25 2001-08-02 EGIS Gyógyszergyár Rt. A process for the preparation of quetiapine and intermediates therefor
WO2002083624A1 (en) * 2001-04-16 2002-10-24 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA979441A (en) * 1967-02-27 1975-12-09 American Cyanamid Company 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines
ES2223294B2 (en) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. PREPARATION PROCEDURE FOR A PHARMACEUTICALLY ACTIVE COMPOUND.
EP1664009B1 (en) * 2003-09-23 2011-01-19 Fermion Oy Preparation method for quetiapine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
WO2001055125A1 (en) * 2000-01-25 2001-08-02 EGIS Gyógyszergyár Rt. A process for the preparation of quetiapine and intermediates therefor
WO2002083624A1 (en) * 2001-04-16 2002-10-24 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CERVENA I ET AL: "1-(-2-(-Hydroxymethylphenylthio)benzyl)-4-methylpiperazine and related compounds as potential antidepressants: Synthesis and pharmacological screening", COLLECT. CZECH. CHEM. COMMUN., vol. 49, no. 4, 1984, pages 1009 - 1020, XP009096062 *
DATABASE BEILSTEIN CROSSFIRE BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, MAIN, DE; 1988, XP002316545 *
WARAWA E J ET AL: "Behavioral approach to nondyskinetic dopamine antagonists: Identification of Seroquel", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 1 February 2001 (2001-02-01), pages 372 - 389, XP002213291, ISSN: 0022-2623 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
US8101597B2 (en) 2007-05-07 2012-01-24 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
US8420807B2 (en) 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine
WO2010100623A1 (en) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
CN101891707A (en) * 2010-07-29 2010-11-24 浙江海正药业股份有限公司 Method for preparing Quetiapine or pharmaceutically acceptable fumarate thereof
CN101891707B (en) * 2010-07-29 2012-10-17 浙江海正药业股份有限公司 Method for preparing Quetiapine or pharmaceutically acceptable fumarate thereof
US9850318B2 (en) 2012-08-21 2017-12-26 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
US10175257B2 (en) 2012-08-21 2019-01-08 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
US9012648B2 (en) 2012-08-21 2015-04-21 Janssen Pharmaceutica Nv Haptens of risperidone and paliperidone
CN104736536A (en) * 2012-08-21 2015-06-24 詹森药业有限公司 Haptens of quetiapine for use in immunoassays
CN104854110A (en) * 2012-08-21 2015-08-19 詹森药业有限公司 Haptens of olanzipine
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
US9303041B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
US9394354B2 (en) 2012-08-21 2016-07-19 Janssen Pharmaceutica Nv Haptens of paliperidone
US9410972B2 (en) 2012-08-21 2016-08-09 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US9465041B2 (en) 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
US9494607B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
US9504682B2 (en) 2012-08-21 2016-11-29 Janssen Pharmaceutica Nv Haptens of aripiprazole
US9611332B2 (en) 2012-08-21 2017-04-04 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
US9664700B2 (en) 2012-08-21 2017-05-30 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US9751953B2 (en) 2012-08-21 2017-09-05 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
CN107266432A (en) * 2012-08-21 2017-10-20 詹森药业有限公司 Quetiapine haptens for immunoassays
US9795685B2 (en) 2012-08-21 2017-10-24 Janssen Pharmaceutica Nv Haptens of aripiprazole
US11385246B2 (en) 2012-08-21 2022-07-12 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
EP3305784A1 (en) * 2012-08-21 2018-04-11 Janssen Pharmaceutica NV Haptens of quetiapine for use in immunoassays
US10166296B2 (en) 2012-08-21 2019-01-01 Janssen Pharmaceutica Nv Haptens of aripiprazole
WO2014031600A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of quetiapine for use in immunoassays
US10288631B2 (en) 2012-08-21 2019-05-14 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10344098B2 (en) 2012-08-21 2019-07-09 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
US10370457B2 (en) 2012-08-21 2019-08-06 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US10379129B2 (en) 2012-08-21 2019-08-13 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
US10379105B2 (en) 2012-08-21 2019-08-13 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
US11225527B2 (en) 2012-08-21 2022-01-18 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US11226345B2 (en) 2012-08-21 2022-01-18 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
US10465013B2 (en) 2012-08-21 2019-11-05 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
US10488401B2 (en) 2012-08-21 2019-11-26 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
US10690686B2 (en) 2012-08-21 2020-06-23 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10712353B2 (en) 2012-08-21 2020-07-14 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
US10793644B2 (en) 2012-08-21 2020-10-06 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
US10816561B2 (en) 2012-08-21 2020-10-27 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
US11105793B2 (en) 2012-08-21 2021-08-31 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
US11046786B2 (en) 2012-08-21 2021-06-29 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
CN103396382A (en) * 2013-07-29 2013-11-20 太仓市茜泾化工有限公司 Preparation method of quetiapine intermediate
US10852313B2 (en) 2015-12-17 2020-12-01 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US11104742B2 (en) 2015-12-17 2021-08-31 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof

Also Published As

Publication number Publication date
DE602004024798D1 (en) 2010-02-04
US20070111987A1 (en) 2007-05-17
CA2538745A1 (en) 2005-03-31
JP2007505864A (en) 2007-03-15
ES2335589T3 (en) 2010-03-30
PT1664007E (en) 2010-02-15
EP1664007A1 (en) 2006-06-07
US7863441B2 (en) 2011-01-04
EP1664007B1 (en) 2009-12-23
AT452882T (en) 2010-01-15

Similar Documents

Publication Publication Date Title
EP1664007B1 (en) Preparation of quetiapine
EP1252151B1 (en) A process for the preparation of quetiapine and intermediates therefor
EP1664009B1 (en) Preparation method for quetiapine
KR100864799B1 (en) Procedure for preparing 11-4-[2-2-hydroxyethoxyethyl]-1-piperazinyl-dibenzo[b,f][1,4]thiazepine
WO2005028457A1 (en) Preparation of quetiapine
US7847094B2 (en) Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine
EP1233954B1 (en) A process for the preparation of 2- 4-(alpha-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy acetic acid and novel intermediates therefor
SK286717B6 (en) Process for preparing a substituted imidazopyridine compound
WO2005073207A1 (en) Process for preparing optically active cetirizine or its salt
EP2749556A1 (en) An improved process for the preparation of pure cyamemazine and salts thereof
HU226639B1 (en) {2-[4-(alpha-phenyl-p-chloro-benzyl)-piperazine-1-yl]-ethoxy}-acetic acid-amides and process for producing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2538745

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006526653

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004767074

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004767074

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007111987

Country of ref document: US

Ref document number: 10572409

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10572409

Country of ref document: US